RVL Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2022
Rhea-AI Summary
RVL Pharmaceuticals plc (Nasdaq: RVLP), a specialty pharmaceutical company, announced its participation in the Barclays Global Healthcare Conference 2022. Key executives, including CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn, will present on March 16, 2022, at 11:15 a.m. ET. The presentation will be available via a webcast, accessible on the company’s website afterward. RVL focuses on developing products for underserved patient populations, with a subsidiary dedicated to ophthalmic and medical aesthetics.
Positive
- None.
Negative
- None.
News Market Reaction – RVLP
In the trading session that priced this news, RVLP declined 1.73%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Barclays Global Healthcare Conference 2022, as follows:
| Date: Time: Webcast: | Wednesday, March 16, 2022 11:15 a.m. ET https://cc.webcasts.com/barc002/031522a_js/?entity=85_1GFQ11B |
The webcast will be available thereafter via the Company’s website www.rvlpharma.com website under the “Investor & News” section.
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc (Nasdaq: RVLP) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc., is the Company’s ophthalmic and medical aesthetics subsidiary supporting UPNEEQ®.
Investor and Media Relations for RVL Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
